ACIU - ACイミュ―ン (AC Immune SA) ACイミュ―ン

 ACIUのチャート


 ACIUの企業情報

symbol ACIU
会社名 AC Immune SA (ACイミュ―ン)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 AC Immune SA is a Switzerland-based company engaged in the medical biotechnology sector. It develops treatments for Alzheimer’s and other neurodegenerative diseases such as Down syndrome glaucoma and Parkinson''s and focuses on producing therapeutic and diagnostic product candidates using SupraAntigen and Morphomer technology platforms. The Company''s pipeline includes Crenezumab ACI-24 Anti-Tau antibody Morphomer Tau Tau-PET imaging agent Morphomer Abeta and Morphomer alpha-syn among others.   ACイミュ―ンはスイスのバイオ医薬品企業。臨床段階で、細胞内のタンパク質の折りたたみ異常に起因する神経変性疾患の特定や治療薬の開発に従事する。広範囲の神経変性疾患を対象にパ―キンソン病、ダウン症、緑内障の予防や診断、治療に対応するために抗体や小分子、ワクチンを作成する。本社はラウサネ。   AC Immune SA engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.
本社所在地 EPFL Innovation Park Building B Lausanne 1015 CHE
代表者氏名 Martin Velasco マーティンベラスコ
代表者役職名 Chairman of the Board of Directors
電話番号 +41 21-345-9121
設立年月日 37653
市場名 NASDAQ National Market System
ipoyear 2016年
従業員数
url www.acimmune.com
nasdaq_url https://www.nasdaq.com/symbol/aciu
adr_tso
EBITDA EBITDA(百万ドル) -28.79702
終値(lastsale) 7.35
時価総額(marketcap) 495115771.5
時価総額 時価総額(百万ドル) 527.14420
売上高 売上高(百万ドル) 21.15660
企業価値(EV) 企業価値(EV)(百万ドル) 424.17964
当期純利益 当期純利益(百万ドル) -27.61319
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 AC Immune SA revenues increased 26% to SF3.5M. Net loss increased 4% to SF22.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Operating Expense - R&D increase of 57% to SF15.2M (expense) Labor_Related Expenses in R&D increase from SF2.2M to SF5.4M (expense).

 ACIUのテクニカル分析


 ACIUのニュース

   The Daily Biotech Pulse: 2 IPOs, Nabriva Pneumonia Drug Gets Canadian Regulatory Nod, PhaseBio Doses First COVID-19 Trial Patient  2020/07/17 11:41:01 Benzinga Feeds
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 16) AC Immune SA (NASDAQ: ACIU ) ( announced clinical trial update for its Alzheimer's vaccine candidate) argenx SE – ADR (NASDAQ: ARGX ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Castle Biosciences Inc (NASDAQ: CSTL ) Dynavax Technologies Corporation (NASDAQ: DVAX )(announced a collaboration with Mt. Sinai to develop a universal influenza vaccine candidate with CpG1018 adjuvant) Heat Biologics Inc (NASDAQ: HTBX ) Novavax, Inc. (NASDAQ: NVAX ) Qiagen NV (NYSE: QGEN )( Thermo Fisher Scientific Inc. (NYSE: TMO ) announced a sweetened offer to buy the company) Quest Diagnostics Inc (NYSE: DGX ) Otonomy Inc (NASDAQ: OTIC ) Principia Biopharma Inc (NASDAQ: PRNB )(reacted to buyout rumors) Relay Therapeutics Inc (NASDAQ: RLAY ) (jumped 75.25% on its debut) Sanofi SA (NASDAQ: SNY ) (Bloomberg reported the French biotech is on a lookout to buy biotech companies, including Principia) TIZIANA LF SCIE/S ADR (NASDAQ: TLSA ) West Pharmaceutical Services Inc. (NYSE: WST ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 16) Avidity Biosciences Inc (NASDAQ: RNA ) Legend Biotech Corp (NASDAQ: LEGN ) Nkarta Inc (NASDAQ: NKTX ) (IPOed last Friday) Repare Therapeutics Inc (NASDAQ: RPTX ) Tricida Inc (NASDAQ: TCDA ) ( received a letter from FDA citing deficiencies in its NDA for the approval of metabolic …
   AC Immune Surges Higher On Alzheimer's Trial Update  2020/07/16 14:57:41 Benzinga
Shares of Swiss biopharma AC Immune SA (NASDAQ: ACIU ) were advancing strongly Thursday following a clinical trial update from the company. What Happened: AC Immune announced positive interim tolerability and immunogenicity results from the initial dosing group in a Phase 1b/2a study of its Alzheimer's disease vaccine candidate ACI-35.030. The company said it has initiated the second-highest dosing group in the study. ACI-35.030, an anti-pTau vaccine, is the second investigational vaccine generated from … Full story available on Benzinga.com
   AC Immune Explodes 56% In Pre-Market On Alzheimer Study Initiation  2020/07/16 12:29:12 Smarter Analyst
Shares in AC Immune (ACIU) are surging 56% in Thursday’s pre-market trading after the biopharma announced the initiation of the second highest dosing … The post AC Immune Explodes 56% In Pre-Market On Alzheimer Study Initiation appeared first on Smarter Analyst .
   AC Immune up big on advancement of Alzheimer's vaccine study (NASDAQ:ACIU)  2020/07/16 11:40:49 Seeking Alpha
Thinly traded small cap AC Immune (NASDAQ:ACIU) jumps 92% premarket in reaction to its announcement that it has initiated the medium dose cohort in its 24-
   AC Immune (ACIU) Reports Q1 Loss, Tops Revenue Estimates  2020/05/04 12:35:03 Zacks Investment Research
AC Immune (ACIU) delivered earnings and revenue surprises of 47.06% and 24.54%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
   AC Immune (ACIU) Reports Q1 Loss, Tops Revenue Estimates  2020/05/04 12:35:03 Zacks Investment Research
AC Immune (ACIU) delivered earnings and revenue surprises of 47.06% and 24.54%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
   AC Immune (ACIU) Moves to Buy: Rationale Behind the Upgrade  2020/02/10 17:00:06 Zacks Investment Research
AC Immune (ACIU) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
   AC Immune (ACIU) Expected to Beat Earnings Estimates: Should You Buy?  2019/11/05 15:33:45 Zacks Investment Research
AC Immune (ACIU) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   AC Immune to Earn Milestone From Lilly for Alzheimer's Drug  2019/09/23 17:22:00 Zacks Investment Research
AC Immune (ACIU) will gain a milestone payment of CHF30 million from partner Eli Lilly for the initiation of the phase I study of ACI-3024, currently being developed to treat Alzheimer's disease.
   Analysts Estimate AC Immune (ACIU) to Report a Decline in Earnings: What to Look Out for  2019/08/07 14:30:34 Zacks Investment Research
AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   AC Immune (ACIU) Reports Q1 Loss, Tops Revenue Estimates  2020/05/04 12:35:03 Zacks Investment Research
AC Immune (ACIU) delivered earnings and revenue surprises of 47.06% and 24.54%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
   AC Immune (ACIU) Moves to Buy: Rationale Behind the Upgrade  2020/02/10 17:00:06 Zacks Investment Research
AC Immune (ACIU) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
   AC Immune (ACIU) Expected to Beat Earnings Estimates: Should You Buy?  2019/11/05 15:33:45 Zacks Investment Research
AC Immune (ACIU) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   AC Immune to Earn Milestone From Lilly for Alzheimer's Drug  2019/09/23 17:22:00 Zacks Investment Research
AC Immune (ACIU) will gain a milestone payment of CHF30 million from partner Eli Lilly for the initiation of the phase I study of ACI-3024, currently being developed to treat Alzheimer's disease.
   Analysts Estimate AC Immune (ACIU) to Report a Decline in Earnings: What to Look Out for  2019/08/07 14:30:34 Zacks Investment Research
AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ACイミュ―ン ACIU AC Immune SA)

 twitter  (公式ツイッターやCEOツイッターなど)